Targeting multiple myeloma cells and their bone marrow microenvironment

被引:39
作者
Pagnucco, G [1 ]
Cardinale, G [1 ]
Gervasi, F [1 ]
机构
[1] ARNAS, Dept Oncol, Div Hematol, I-90100 Palermo, Italy
来源
SIGNAL TRANSDUCTION AND COMMUNICATION IN CANCER CELLS | 2004年 / 1028卷
关键词
multiple myeloma; bone marrow microenvironment; novel therapies;
D O I
10.1196/annals.1322.047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although multiple myeloma (MM) is sensitive to chemotherapy and radiation therapy, long-term disease-free survival is rare, and MM remains incurable despite conventional and high-dose therapies. Direct (cell-cell contact) and soluble (via cytokines) forms of interactions between MM cells and bone marrow stroma regulate growth, survival, and homing of MM cells. These interactions also play a critical role in angiogenesis and in myeloma bone disease. In recent years, several studies have established the biologic significance of cytokines in MM pathogenesis and delineated signaling cascades mediating their effects, providing the framework for related novel therapies targeting not only the MM cell, but also the bone marrow microenvironment.
引用
收藏
页码:390 / 399
页数:10
相关论文
共 69 条
[1]   Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Moriyama, K ;
Hashimoto, T ;
Ozaki, S ;
Wakatsuki, S ;
Kosaka, M ;
Kido, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2002, 100 (06) :2195-2202
[2]   Moving disease biology from the lab to the clinic [J].
Anderson, KC .
CANCER, 2003, 97 (03) :796-801
[3]   Treatment of multiple myeloma [J].
Barlogie, B ;
Shaughnessy, J ;
Tricot, G ;
Jacobson, J ;
Zangari, M ;
Anaissie, E ;
Walker, R ;
Crowley, J .
BLOOD, 2004, 103 (01) :20-32
[4]  
Barlogie B, 2001, SEMIN ONCOL, V28, P577
[5]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[6]   Peptidomimetic antagonists of αvβ3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone [J].
Carron, CP ;
Meyer, DM ;
Engleman, VW ;
Rico, JG ;
Ruminski, PG ;
Ornberg, RL ;
Westlin, WF ;
Nickols, GA .
JOURNAL OF ENDOCRINOLOGY, 2000, 165 (03) :587-598
[7]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[8]   Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism [J].
Chauhan, D ;
Pandey, P ;
Ogata, A ;
Teoh, G ;
Treon, S ;
Urashima, M ;
Kharbanda, S ;
Anderson, KC .
ONCOGENE, 1997, 15 (07) :837-843
[9]   Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B [J].
Chauhan, D ;
Uchiyama, H ;
Akbarali, Y ;
Urashima, M ;
Yamamoto, K ;
Libermann, TA ;
Anderson, KC .
BLOOD, 1996, 87 (03) :1104-1112
[10]   IL-6 switches the differentiation of monocytes from dendritic cells to macrophages [J].
Chomarat, P ;
Banchereau, J ;
Davoust, J ;
Palucka, AK .
NATURE IMMUNOLOGY, 2000, 1 (06) :510-514